Cargando…

Population-based study of “no evident disease activity” in MS

OBJECTIVE: To determine the persistence of no evident disease activity (NEDA) in a population-based relapsing-remitting MS (RRMS) cohort. METHODS: All incident cases of RRMS in Olmsted County between 2000 and 2011 were identified using a medical records linkage system. Persistence of NEDA after RRMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Parks, Natalie E., Pittock, Sean J., Mandrekar, Jay, Kantarci, Orhun H., Lucchinetti, Claudia F., Weinshenker, Brian G., Keegan, B. Mark, Tobin, W. Oliver, Tillema, Jan-Mendelt, Toledano, Michel, Flanagan, Eoin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134213/
https://www.ncbi.nlm.nih.gov/pubmed/30211251
http://dx.doi.org/10.1212/NXI.0000000000000495
_version_ 1783354636677152768
author Parks, Natalie E.
Pittock, Sean J.
Mandrekar, Jay
Kantarci, Orhun H.
Lucchinetti, Claudia F.
Weinshenker, Brian G.
Keegan, B. Mark
Tobin, W. Oliver
Tillema, Jan-Mendelt
Toledano, Michel
Flanagan, Eoin P.
author_facet Parks, Natalie E.
Pittock, Sean J.
Mandrekar, Jay
Kantarci, Orhun H.
Lucchinetti, Claudia F.
Weinshenker, Brian G.
Keegan, B. Mark
Tobin, W. Oliver
Tillema, Jan-Mendelt
Toledano, Michel
Flanagan, Eoin P.
author_sort Parks, Natalie E.
collection PubMed
description OBJECTIVE: To determine the persistence of no evident disease activity (NEDA) in a population-based relapsing-remitting MS (RRMS) cohort. METHODS: All incident cases of RRMS in Olmsted County between 2000 and 2011 were identified using a medical records linkage system. Persistence of NEDA after RRMS diagnosis was determined by retrospective chart review. MRI activity, relapse, or Expanded Disability Status Scale (EDSS) worsening resulted in failure of NEDA. RESULTS: We identified 93 incident cases of RRMS including 82 individuals with sufficient follow-up to determine the persistence of NEDA. There were 44 individuals not on disease-modifying therapy (DMT), whereas 37 individuals were prescribed an injectable DMT and 1 received mitoxantrone during the interval over which NEDA was maintained. NEDA was maintained by 63% at 1 year, 38% at 2 years, 19% at 5 years, and 12% at 10 years according to routine care assessment. At 10 years, there was no difference in EDSS disability among patients who maintained NEDA vs those who failed NEDA at 1 year (p = 0.3). CONCLUSIONS: NEDA infrequently persists beyond 2 years in a population-based cohort of newly diagnosed patients with RRMS.
format Online
Article
Text
id pubmed-6134213
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61342132018-09-12 Population-based study of “no evident disease activity” in MS Parks, Natalie E. Pittock, Sean J. Mandrekar, Jay Kantarci, Orhun H. Lucchinetti, Claudia F. Weinshenker, Brian G. Keegan, B. Mark Tobin, W. Oliver Tillema, Jan-Mendelt Toledano, Michel Flanagan, Eoin P. Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To determine the persistence of no evident disease activity (NEDA) in a population-based relapsing-remitting MS (RRMS) cohort. METHODS: All incident cases of RRMS in Olmsted County between 2000 and 2011 were identified using a medical records linkage system. Persistence of NEDA after RRMS diagnosis was determined by retrospective chart review. MRI activity, relapse, or Expanded Disability Status Scale (EDSS) worsening resulted in failure of NEDA. RESULTS: We identified 93 incident cases of RRMS including 82 individuals with sufficient follow-up to determine the persistence of NEDA. There were 44 individuals not on disease-modifying therapy (DMT), whereas 37 individuals were prescribed an injectable DMT and 1 received mitoxantrone during the interval over which NEDA was maintained. NEDA was maintained by 63% at 1 year, 38% at 2 years, 19% at 5 years, and 12% at 10 years according to routine care assessment. At 10 years, there was no difference in EDSS disability among patients who maintained NEDA vs those who failed NEDA at 1 year (p = 0.3). CONCLUSIONS: NEDA infrequently persists beyond 2 years in a population-based cohort of newly diagnosed patients with RRMS. Lippincott Williams & Wilkins 2018-08-16 /pmc/articles/PMC6134213/ /pubmed/30211251 http://dx.doi.org/10.1212/NXI.0000000000000495 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Parks, Natalie E.
Pittock, Sean J.
Mandrekar, Jay
Kantarci, Orhun H.
Lucchinetti, Claudia F.
Weinshenker, Brian G.
Keegan, B. Mark
Tobin, W. Oliver
Tillema, Jan-Mendelt
Toledano, Michel
Flanagan, Eoin P.
Population-based study of “no evident disease activity” in MS
title Population-based study of “no evident disease activity” in MS
title_full Population-based study of “no evident disease activity” in MS
title_fullStr Population-based study of “no evident disease activity” in MS
title_full_unstemmed Population-based study of “no evident disease activity” in MS
title_short Population-based study of “no evident disease activity” in MS
title_sort population-based study of “no evident disease activity” in ms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134213/
https://www.ncbi.nlm.nih.gov/pubmed/30211251
http://dx.doi.org/10.1212/NXI.0000000000000495
work_keys_str_mv AT parksnataliee populationbasedstudyofnoevidentdiseaseactivityinms
AT pittockseanj populationbasedstudyofnoevidentdiseaseactivityinms
AT mandrekarjay populationbasedstudyofnoevidentdiseaseactivityinms
AT kantarciorhunh populationbasedstudyofnoevidentdiseaseactivityinms
AT lucchinetticlaudiaf populationbasedstudyofnoevidentdiseaseactivityinms
AT weinshenkerbriang populationbasedstudyofnoevidentdiseaseactivityinms
AT keeganbmark populationbasedstudyofnoevidentdiseaseactivityinms
AT tobinwoliver populationbasedstudyofnoevidentdiseaseactivityinms
AT tillemajanmendelt populationbasedstudyofnoevidentdiseaseactivityinms
AT toledanomichel populationbasedstudyofnoevidentdiseaseactivityinms
AT flanaganeoinp populationbasedstudyofnoevidentdiseaseactivityinms